
Last updated: 2026-09-16 09:04:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
ArriVent BioPharma, Inc. (AVBP) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $27,99, with a market capitalisation of $1,41B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $17,00 to $35,83. This page covers its latest market performance, valuation, price trends and company information.
$1,41B | |
$27,99 | |
$36,37 | |
$14,35 | |
$27,97 | |
672,00 | |
530,82K | |
-- | |
$35,83 | |
$17,00 | |
-- | |
-- |
ArriVent BioPharma, Inc. (AVBP) is trading at $27,99 in pre-market trading as of 2026-09-16 08:52:00, up 0,05% ($0,02) from the previous close of $27,97
Pre-market trading shows how investors are pricing AVBP before the regular session opens. The current pre-market price is near the previous close, indicating positive early trading sentiment.
Over the past seven days, ArriVent BioPharma, Inc. (AVBP) moved from $30,95 to $27,99, representing a decline of 9,58% ($2,97).
The stock traded between $27,70 and $31,45 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 536,70 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 58,3%
AVBP is currently trading at $27,99, placing it 58,3% of the way from its 52-week low of $17,00 to its 52-week high of $35,83. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. The company focuses on advancing its lead product candidate, firmonertinib, for the treatment of epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC), and developing a pipeline of novel therapeutics, including next-generation antibody-drug conjugates such as ARR-217 (MRG007), with an initial focus on solid tumors.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 77 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of ArriVent BioPharma, Inc. (AVBP) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.